Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Moso MA, Anderson JL, Adikari S, Gray LR, Khoury G, Chang JJ, Jacobson JC, Ellett AM, Cheng WJ, Saleh S, Zaunders JJ, Purcell DFJ, Cameron PU, Churchill MJ, Lewin SR, Lu HK.

AIDS. 2019 Feb 1;33(2):199-209. doi: 10.1097/QAD.0000000000002075.

PMID:
30562171
2.

Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.

Flynn JK, Ellenberg P, Duncan R, Ellett A, Zhou J, Sterjovski J, Cashin K, Borm K, Gray LR, Lewis M, Jubb B, Westby M, Lee B, Lewin SR, Churchill M, Roche M, Gorry PR.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1220-1235. doi: 10.1089/AID.2017.0097. Epub 2017 Sep 26.

PMID:
28797170
3.

Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.

Gray LR, On H, Roberts E, Lu HK, Moso MA, Raison JA, Papaioannou C, Cheng WJ, Ellett AM, Jacobson JC, Purcell DF, Wesselingh SL, Gorry PR, Lewin SR, Churchill MJ.

J Neurovirol. 2016 Aug;22(4):455-63. doi: 10.1007/s13365-015-0413-4. Epub 2016 Jan 4.

PMID:
26727904
4.

Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.

Lee TT, Chana G, Gorry PR, Ellett A, Bousman CA, Churchill MJ, Gray LR, Everall IP.

J Neurovirol. 2015 Oct;21(5):535-43. doi: 10.1007/s13365-015-0354-y. Epub 2015 Jun 3.

5.

HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles.

Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H, Roche MJ, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2014 Feb 28;9(2):e90620. doi: 10.1371/journal.pone.0090620. eCollection 2014.

6.

Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains.

Flynn JK, Paukovics G, Cashin K, Borm K, Ellett A, Roche M, Jakobsen MR, Churchill MJ, Gorry PR.

Viruses. 2014 Feb 10;6(2):709-26. doi: 10.3390/v6020709.

7.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

8.

Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.

Jakobsen MR, Cashin K, Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Ostergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR.

PLoS One. 2013 Jun 18;8(6):e65950. doi: 10.1371/journal.pone.0065950. Print 2013.

9.

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

Gray LR, Tachedjian G, Ellett AM, Roche MJ, Cheng WJ, Guillemin GJ, Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2013 Apr 16;8(4):e62196. doi: 10.1371/journal.pone.0062196. Print 2013.

10.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

11.

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.

Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M.

Virology. 2013 Jul 20;442(1):51-8. doi: 10.1016/j.virol.2013.03.026. Epub 2013 Apr 17.

12.

Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, Ellett A, Wesselingh SL, Ramsland PA, Lee B, Churchill MJ, Gorry PR.

J Leukoc Biol. 2013 Jan;93(1):113-26. doi: 10.1189/jlb.0612308. Epub 2012 Oct 17.

13.

Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.

Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR.

Virology. 2012 Oct 25;432(2):394-404. doi: 10.1016/j.virol.2012.06.024. Epub 2012 Jul 19.

14.

A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA.

Hooker DJ, Mobarok M, Anderson JL, Rajasuriar R, Gray LR, Ellett AM, Lewin SR, Gorry PR, Cherry CL.

Nucleic Acids Res. 2012 Aug;40(15):e113. Epub 2012 Apr 28.

15.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.

Retrovirology. 2011 Nov 7;8:89. doi: 10.1186/1742-4690-8-89.

16.

Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 Oct;85(20):10699-709. doi: 10.1128/JVI.05510-11. Epub 2011 Aug 10.

17.

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 May;85(9):4330-42. doi: 10.1128/JVI.00106-11. Epub 2011 Feb 23.

18.

CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity.

Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR.

Virology. 2011 Feb 20;410(2):418-28. doi: 10.1016/j.virol.2010.12.010. Epub 2011 Jan 8.

19.

CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates.

Gray LR, Gabuzda D, Cowley D, Ellett A, Chiavaroli L, Wesselingh SL, Churchill MJ, Gorry PR.

J Neurovirol. 2011 Feb;17(1):82-91. doi: 10.1007/s13365-010-0001-6. Epub 2010 Nov 30.

20.

Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders.

Padiglione A, Aleksic E, French M, Arnott A, Wilson KM, Tippett E, Kaye M, Gray L, Ellett A, Crane M, Leslie DE, Lewin SR, Breschkin A, Birch C, Gorry PR, McPhee DA, Crowe SM.

Clin Immunol. 2010 Nov;137(2):199-208. doi: 10.1016/j.clim.2010.07.003. Epub 2010 Aug 8.

PMID:
20696618

Supplemental Content

Loading ...
Support Center